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Objectives: The avian inﬂuenza H7N9 virus can cause cytokine overproduction and result in severe
pneumonia and acute respiratory distress syndrome. Many studies have focused on hypercytokinemia
during avian inﬂuenza infection. This study examined the association between C-reactive protein (CRP)
and cytokines.
Methods: The plasma cytokine and chemokine proﬁles of 57 H7N9 patients were investigated using a
multiplex immunoassay. The CRP levels of patients with H7N9 and patients with H1N1 were also
compared. Further, the association between cytokines and CRP in H7N9 infections was explored.
Results: Compared with H1N1 virus, it was found that H7N9 virus induced higher expression of CRP,
leading to cytokine storms. Several cytokines, including MIP-1b, MCP-1, IP-10, and IL-6, were observed
to have signiﬁcantly positive relationships with CRP levels, whereas IL-17A was negatively associated
with CRP levels.
Conclusions: These ﬁndings suggest that CRP may be used as an early indicator to identify high-risk
patients, to assess disease progression, and to determine the development of hypercytokinemia.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Inﬂuenza A H7N9, a newly emerging avian virus that was ﬁrst
identiﬁed in China in March 2013, has resulted in 571 laboratory-
conﬁrmed cases of human infection and 212 reported deaths.1 In
addition to the common features of fever and cough, H7N9 virus-
infected patients present with severe pneumonia and acute
respiratory distress syndrome (ARDS), accompanied by fatal
outcomes.2,3 Similar to H5N1, H7N9 has been shown to cause
hypercytokinemia in both plasma and lung tissues.4,5 Hypercyto-
kinemia is considered both an immune response and a critical
pathogenic factor.6,7 Previous studies have reported that several
speciﬁc cytokines are highly associated with disease severity and
outcomes.8
C-reactive protein (CRP) is synthesized primarily by the liver,9
and is one of the non-speciﬁc acute-phase proteins produced in
response to most forms of infection, inﬂammation, and tissue* Corresponding author. Tel.: +86 571 8723 6458; fax: +86 571 8723 6459.
E-mail address: ljli@zju.edu.cn (L. Li).
1 Wenrui Wu, Ding Shi, and Daiqiong Fang contributed equally to this work.
http://dx.doi.org/10.1016/j.ijid.2016.01.009
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).injury. Thus, this protein has been considered a non-speciﬁc
biomarker for early diagnosis and prognostic measurements.10,11
Speciﬁcally, CRP exhibits superior diagnostic value for bacterial
infections with high plasma concentrations. However, CRP levels
remain normal or increase only slightly during most viral
infections.12 As reported previously, patients with H7N9 have
signiﬁcantly higher CRP levels compared to patients with H1N1,13
another subtype of avian inﬂuenza virus. Moreover, signiﬁcantly
higher CRP expression in patients with H7N9 positively correlates
with disease severity.14
Previous studies have compared the roles of CRP, angiotensin
II,15 and several cytokines8 in predicting the progression and
outcome of inﬂuenza infections and have suggested that angio-
tensin II is a good biomarker and that speciﬁc cytokines are good
predictors of the outcome. There is no doubt that the early
identiﬁcation of high-risk cases and the monitoring of illness
progression greatly contribute to appropriate clinical decision-
making. However, current cytokine and angiotensin II measure-
ment techniques are either costly or complicated, thus easier
examination methods are required to identify high-risk cases.
Moreover it was considered of interest to determine the
mechanism by which the virulent inﬂuenza virus H7N9 causes aciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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between CRP and these cytokines. This study investigated
inﬂammatory cytokine and CRP levels in patients with H7N9
and H1N1 infections and analyzed the possible correlation
between cytokines and CRP.
2. Patients and methods
2.1. Patients and associated procedures
From April 2013 to February 2014, 82 patients with laboratory-
conﬁrmed H7N9 infections were recruited at the First Afﬁliated
Hospital, College of Medicine, Zhejiang University. Fourteen
patients with H1N1 virus in Beijing from December 2012 to
February 2013 were also recruited, as well as six healthy
volunteers as controls. The presence of H7N9 and H1N1 viruses
was conﬁrmed using protocols described previously.14,16,17 Plasma
samples were collected within 2 days of admission. Patient sputum
samples or pharyngeal swabs were collected on the same day.
Twenty-ﬁve patients with H7N9 were excluded because their
plasma samples were collected more than 10 days after the onset
of fever. Data on clinical characteristics were collected on the same
day as plasma sampling (Table 1). Blood samples were obtained
using ethylenediaminetetraacetic acid (EDTA) anticoagulant tubes
and centrifuged to collect plasma. Viral load was detected by
TaqMan real-time reverse transcription PCR targeting the inﬂuen-
za A H7N9 virus subtype-speciﬁc H7 gene or inﬂuenza A H1N1
virus subtype-speciﬁc H1 and N1 genes using standard thermal
cycling conditions.18,17,19 All of the specimens were stored at
80 8C until analysis. This study complied with the necessary
ethical guidelines and was approved by the Research Ethics Board
of the First Afﬁliated Hospital of Zhejiang University. All
participants or their guardians signed an informed consent form
before enrolment.
2.2. Measurement of cytokine and chemokine concentrations in
patient plasma
A 27-plex assay kit was used to measure the concentrations of
plasma cytokines (Bio-Plex Pro Human 27-plex cytokine group I;
Bio-Rad, CA, USA); the manufacturer’s protocol was followed. The
27-plex assay contains the following cytokines: basic ﬁbroblast
growth factor (FGF), EOTAXIN, granulocyte colony-stimulatingTable 1
Characteristics of the patients with H7N9 and H1N1 infections included in the study
Characteristics H7N9 H1N1
Number 57 14
Age, years, median (range) 62 (21–86) 54 (26–85)
Male sex, n/total n (%) 36/57 (63.2%) 9/14 (64.3%)
History of conﬁrmed poultry
contact, n/total n (%)
28/57 (49.1%) NA
History of conﬁrmed contact
with a patient with H7N9
infection, n/total n (%)
2 /57 (3.5%) NA
Antiviral therapy before
sampling, n/total n (%)
41/57 (71.9%) 9/14 (64.3%)
ARDS (%) 37/57 (64.9%) 3/14 (21.4%)
Days from onset of fever to
sampling
6.7  2.2 7.75  3.38
CRP, mg/l 84.0  65.2 11.37  6.70
White blood cell count, 109/l 5.6  4.4 5.76  2.82
Neutrophils, 109/l 4.8  4.1 4.17  2.80
Median Ct value of initial
viral load (n)
30 (33) 30 (12)
Clinical outcome of death,
n/total n (%)
18/57 (31.6%) 0 (0)
ARDS, acute respiratory distress syndrome; CRP, C-reactive protein; Ct, cycle
threshold; NA, not available.factor (G-CSF), granulocyte–macrophage colony-stimulating factor
(GM-CSF), interferon-gamma (IFN-g), interleukin (IL)-10, IL-12
(p70), IL-13, IL-15, IL-17A, IL-1 receptor antagonist (Ra), IL-2, IL-4,
IL-5, IL-6, IL-7, IL-8, IL-9, IFN-g-induced protein 10 (IP-10), IL-1b,
monocyte chemotactic protein 1 (MCP-1), macrophage inﬂammato-
ry protein 1 alpha (MIP-1a), MIP-1b, platelet-derived growth factor
BB (PDGF-BB), RANTES (Regulated on Activation, Normal T Cell
Expressed and Secreted), tumor necrosis factor alpha (TNF-a), and
vascular endothelial growth factor (VEGF). Samples were analyzed
using a MAGPIX system (Luminex Corporation, Merck Millipore,
Temecula, CA, USA), and the data were processed using Bio-Plex
Manager 6.1 software (Bio-Rad). Cytokine/chemokine values that
were detected outside of the standard range were ﬂagged as high or
low out-of-range (OOR), and the highest or lowest value on the
standard curve was used instead of the OOR measurement. IL-15 and
IL-1b measurements were excluded because more than 50% of the
values were OOR below the standard curve.
2.3. Measurement of CRP in patient plasma
CRP was detected using a Beckman-Coulter IMMAGE
800 Immunohistochemistry System and Beckman-Coulter
reagents (Beckman-Coulter, Brea, CA, USA).20
2.4. Statistical analysis
Results are expressed as the mean  standard deviation, or the
median, as appropriate. Differences between groups were evaluated
by unpaired t-test or one-way analysis of variance (ANOVA).
Pearson’s correlation coefﬁcient and Spearman’s rank correlation
coefﬁcient were used for linear correlation analysis. Statistical
analyses were performed using IBM SPSS Statistics version 19.0 soft-
ware (IBM Corp., Armonk, NY, USA), and ﬁgures were generated with
GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA).
A p-value of <0.05 was considered statistically signiﬁcant.
3. Results
3.1. Characteristics of the study subjects
The characteristics of the patients are shown in Table 1. The
median age of the patients with H7N9 infection was 62 years, and
36 patients (63.2%) were male. Twenty-eight patients (49.1%) had a
contact history with poultry, and two patients had a contact
history with a patient infected with H7N9. The mean interval from
fever onset to sampling was 6.7  2.2 days for the patients with
H7N9 and 7.75  3.38 days for the patients with H1N1. The patients
with H7N9 were more likely to progress to ARDS (64.9%) than the
patients with H1N1 (21.4%). Forty-one (71.9%) patients with H7N9
were treated with antiviral drugs before sampling compared to 64.3%
of patients with H1N1. The CRP levels were much higher in patients
with H7N9 infection than in patients with H1N1 infection
(84.0  65.2 compared to 11.37  6.70 mg/l, p < 0.01). However,
the white blood cell and neutrophil counts were within the normal
range in both groups (Table 1). The median cycle threshold (Ct) values
of the H7N9 and H1N1 viruses were both 30. The overall mortality of
patients with H7N9 infection was 31.6%, and that for patients with
H1N1 was 0%.
3.2. Comparison of plasma CRP levels between H1N1 and H7N9
Based on clinical outcomes, the patients with H7N9 were
divided into two groups, a survivor group and a non-survivor
group. The CRP plasma levels of these two groups were compared
with that of the H1N1 group. The CRP concentration of the H1N1
group was signiﬁcantly lower than those in the survivor (p < 0.01)
Figure 1. Comparison of plasma CRP levels between patients with H1N1 and patients
with H7N9. H1N1, H1N1-infected group; SURVIVAL, H7N9-infected survivors;
DEATH, H7N9-infected non-survivors. The data represent the mean  standard
deviation (H1N1, n = 14; SURVIVAL, n = 39; DEATH, n = 18; **p < 0.01).
Table 2
Correlation of CRP with cytokines in patients with H7N9 infection
Cytokine Pearson/Spearman r p-Value
Basic FGFb 0.1915 0.1536
EOTAXINb 0.2979 0.0244c
G-CSFb 0.02314 0.8643
GM-CSFb 0.08345 0.5371
IFN-gb 0.1378 0.3067
IL-10b 0.08414 0.5338
IL-12 (p70)b 0.2326 0.0817
IL-13b 0.1340 0.3203
IL-17Aa 0.3020 0.0224c
IL-1Rab 0.06116 0.6513
IL-2b 0.2601 0.0507
IL-4b 0.2018 0.1322
IL-5b 0.2254 0.0918
IL-6b 0.3041 0.0215c
IL-7b 0.2210 0.0986
IL-8b 0.1008 0.4558
IL-9b 0.1889 0.1593
IP-10b 0.3044 0.0213c
MCP-1a 0.3885 0.0028c
MIP-1ab 0.07860 0.5611
MIP-1ba 0.5507 <0.0001c
PDGF-BBb 0.2482 0.0627
RANTESb 0.3385 0.0100c
TNF-ab 0.2039 0.1281
VEGFb 0.1112 0.4101
CRP, C-reactive protein; FGF, ﬁbroblast growth factor; G-CSF, granulocyte colony-
stimulating factor; GM-CSF, granulocyte–macrophage colony-stimulating factor;
IFN, interferon; IL, interleukin; IP, IFN-g-induced protein; MCP, monocyte
chemotactic protein; MIP, macrophage inﬂammatory protein; PDGF, platelet-
derived growth factor; RANTES, Regulated on Activation, Normal T Cell Expressed
and Secreted; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
a Calculation of the Pearson correlation coefﬁcient of CRP with the cytokine (in
log10).
b Calculation of the Spearman rank correlation coefﬁcient of CRP with the
cytokine.
c p < 0.05.
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H7N9 who died had much higher concentrations of CRP
(129.6  63.9 mg/l) than the patients who survived
(63.0  54.8 mg/l) (p < 0.01).
3.3. Correlation of CRP with cytokines in patients with H7N9 infection
A linear correlation analysis of CRP with the expression of all
measured cytokines was performed for the H7N9 infection group
(Table 2). The concentrations of seven cytokines/chemokines were
signiﬁcantly correlated with CRP levels. In addition, the CRP levels
in patients with H7N9 infection within 10 days of fever onset
demonstrated a strong positive linear correlation with MIP-1b
(r = 0.5507, p < 0.0001) (Figure 2B), modest positive linear
correlations with MCP-1 (r = 0.3885, p = 0.0028), IP-10
(r = 0.3044, p = 0.0213), and IL-6 (r = 0.3041, p = 0.0215)
(Figure 2C–E), and modest negative linear correlations with
IL-17A (r = 0.3020, p = 0.0224), RANTES (r = 0.3385,
p = 0.0100), and EOTAXIN (r = 0.2979, p = 0.0244) (Figure 2F–
H). The quartiles and minimum and maximum values of the seven
cytokines listed above in the H7N9 infection, H1N1 infection, and
healthy groups are shown in Figure 2A. MCP-1, IP-10, IL-6, and
IL-17A levels in the H7N9 infection group were signiﬁcantly
elevated compared to those in the H1N1 virus-infected and healthy
groups. The plasma levels of MIP-1b and RANTES were also higher
in the two patient groups than in the healthy individuals.
Furthermore, the concentration of plasma MIP-1b was higher in
H7N9-infected patients than in H1N1-infected patients, although
this trend did not pass hypothesis testing. Furthermore, EOTAXIN
levels did not differ among the three groups. Correlations between
CRP and the other measured cytokines in H7N9 infection were not
signiﬁcant (p > 0.05) (Table 2).
3.4. Correlation of seven cytokines with Ct values of viral load in
patients with H7N9 infection
Based on the above ﬁndings, linear correlation analysis of these
seven cytokines with Ct values of H7N9 virus was performed
(Supplementary Material, Table S1). Plasma levels of MIP-1b,MCP-1, IP-10, and IL-6 were highly associated with Ct values of the
H7N9 virus in a small H7N9-infected patient group (r = 0.411,
p = 0.017; r = 0.481, p = 0.005; r = 0.557, p = 0.001; r = 0.394,
p = 0.023, respectively; n = 33). However, there were no signiﬁcant
correlations between the other three cytokines and Ct values.
4. Discussion
This study investigated both inﬂammatory cytokine and CRP
levels during H7N9 infections and explored their possible correla-
tion. By comparing CRP levels in different groups, it was noted that
patients infected with H7N9 were more likely to exhibit high CRP
expression levels; however, patients with high levels of CRP had
poor outcomes. It was also observed that the levels of several
cytokines, including MIP-1b, MCP-1, IP-10, IL-6, IL-17A, RANTES,
and EOTAXIN, were signiﬁcantly associated with CRP levels.
Hypercytokinemia (also known as a ‘cytokine storm’) is
characterized by the over-production of various proinﬂammatory
cytokines and plays an important role in disease severity and fatal
outcomes in patients with H5N1 infection.6 Compared with H1N1
infection, H7N9 virus infection tends to induce higher cytokine
expression, resembling the cytokine storm observed in H5N1
infection.18 Similarly, hypercytokinemia also correlates positively
with the deterioration of H7N9 infection, indicating that advanced
detection of a cytokine storm and the determination of severe
cases are necessary. In this work, it was hypothesized that CRP
would be a simple and convenient but non-functional marker for
the early prediction of potential cytokine storms.
MCP-1 (CCL-2) and MIP-1b (CCL-4) belong to the CCL family
and are two chemokines that primarily affect the recruitment of
monocyte/macrophages to inﬂammatory sites,21 thus mediating
Figure 2. (A) Plasma MIP-1b, MCP-1, IP-10, IL-6, IL-17A, RANTES, and EOTAXIN levels in the H7N9 infection, H1N1 infection, and healthy groups within 10 days of fever onset.
Quartiles and minimum and maximums values are presented. *Comparison between the healthy group and the H7N9 group. #Comparison between the H7N9 and H1N1
groups, p < 0.05. (B)–(H) Correlation between CRP and plasma cytokine levels (MIP-1b, MCP-1, IP-10, IL-6, IL-17A, RANTES, EOTAXIN) in patients with H7N9 infection and
fever. The Pearson correlation coefﬁcient (r), Spearman rank correlation coefﬁcient (r), and p-values are provided in each graph.
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and MIP-1b levels increase in patients with H7N9.14,18 In this
study, it was found that MCP and MIP-1b had signiﬁcant positive
relationships with CRP, and the latter displayed a much stronger
relationship. Furthermore, both of these were highly related to the
initial viral load in H7N9 infection (Supplementary Material,Table S1), which has been reported previously for H5N1 and H7N9
infection.6,14 MIP-1b levels are higher in patients with H7N9 than
in patients with H5N1.18 Moreover, MIP-1b levels correlate
positively with poor clinical outcomes.4 Because CRP levels are
also related to disease severity, the correlation between chemo-
kines and CRP may be obvious. However, CRP can also mediate the
W. Wu et al. / International Journal of Infectious Diseases 44 (2016) 31–36 35secretion of CC chemokines from monocytes, including MCP-1 and
MIP-1b,22 leading us to hypothesize that CRP, the primary acute
phase protein, might participate in the pathogenesis of H7N9
infections as a secondary inducer of chemokines in addition to
direct stimulation by the inﬂuenza virus.
IP-10 is a proinﬂammatory cytokine that is secreted by a variety
of cells, including monocytes, ﬁbroblasts, endothelial cells, and
hepatocytes.23 As a member of the CXC chemokine family, IP-10
can recruit and activate T-cells, monocytes/macrophages, natural
killer (NK) cells, eosinophils, and dendritic cells.23–26 IP-10 is
elevated in patients with H5N1 infection, particularly in patients
who die,6 and a similar elevation has also been detected in patients
with H7N9 infection, with severe cases exhibiting signiﬁcantly
higher levels of IP-10.7,8 Moreover, the IP-10 plasma levels
correlate with the inﬂuenza virus load in patients with both
H5N1 and H7N9 infections,6,8 which was also found in the present
study (Supplementary Material, Table S1). Patients with H7N9
infection share unusually high CRP plasma levels with H5N1
patients, a phenomenon not observed in patients with H1N1
infection.13 Therefore, the relationship between IP-10 and CRP was
studied and a positive correlation was observed. As reported
previously, IP-10 plays a critical role in the earliest stages of acute
lung injury.27,28 In this study, simultaneously elevated CRP and IP-
10 levels were detected, suggesting that IP-10 may cause the
increased expression of plasma CRP.
IL-6 levels are increased in patients with H7N9 infection and are
signiﬁcantly higher in patients with severe infections. High levels
of IL-6 have also been associated with poor clinical outcomes.4 In
this study, a positive correlation between CRP and IL-6 levels was
observed. IL-6 induces CRP gene expression in hepatocytes.29
Moreover, IL-6-blocking therapies can restore normal plasma CRP
levels in chronic inﬂammatory diseases,30 and the underlying
mechanism has been reported.31 It was considered that after
infection with H7N9, increased IL-6 levels may also induce CRP
expression.
IL-17A (usually referred to as IL-17) was initially described as a
characteristic cytokine secreted by Th17 lymphocytes, NK T-cells
(NKT), gd T-cells, and CD8+ T-cells.32,33 IL-17A stimulates
proinﬂammatory chemokines and recruits neutrophils into the
airway.34 IL-17A plays a signiﬁcantly defensive role in various
infections,33 and is involved in asthma.35 In patients with chronic
obstructive pulmonary disease (COPD), IL-17A levels increase as
the disease progresses, and the serum levels positively correlate
with CRP.36 In patients with H7N9 infection, high plasma
concentrations of IL-17A were detected, consistent with previous
data.7 However, intriguingly, IL-17A was negatively correlated
with CRP in the present study. Previous studies have indicated that
IL-17A primarily promotes neutrophilic inﬂammation.37–39 Addi-
tional studies are needed to clarify the exact role of IL-17A in H7N9
infection and the underlying mechanism between IL-17A and CRP
levels.
RANTES (CCL5) is a small 68-amino acid protein that belongs to a
rapidly growing chemokine family. It can be strongly induced by
viral and bacterial infections and recruits T-cells, dendritic cells,
eosinophils, NK cells, mast cells, and basophils to sites of
inﬂammation and infection.40 EOTAXIN is another chemokine with
potent and selective agonist activity for CC chemokine receptor 3,
which can attract eosinophils to sites of inﬂammation. In the
present study, it was observed that the CRP levels 10 days from fever
onset in patients with H7N9 infection had a negative linear
correlation with both RANTES and EOTAXIN, which was contradic-
tory to the hypothesis. For this reason, the two chemokines were
compared between the groups. There was no signiﬁcant difference
in the plasma levels of RANTES or EOTAXIN between the H7N9- and
the H1N1-infected patients (Figure 2A), which is consistent with
previous ﬁndings in H7N9- and H5N1-infected patients.6,7 It issupposed that the negative correlations of CRP with RANTES and
EOTAXIN may result from signiﬁcant differences without biological
relevance, which should be conﬁrmed further in a larger number of
subjects.
In accordance with previous studies,13,14 H7N9 patients
presented with high levels of CRP. This elevated acute phase
protein was related to disease severity, indicating an underlying
secondary bacterial infection. Although cytokine storms reﬂect a
host defense response against pathogens, the overwhelming levels
of activated factors could cause immunity injury and contribute to
pathogenesis. Nonetheless, the immunopathological mechanism
of H7N9 infection remains unclear. It was hypothesized that in
addition to various cytokines, CRP also plays an important role in
the progression of this disease. Certain connections between CRP
and cytokines exist that form a complicated inﬂammatory
network, suggesting that this acute-phase protein might reﬂect
the release of inﬂammatory factors to a certain extent. Moreover,
no correlation was found between CRP and the initial viral load in
H7N9 infection (data not shown), which indicates that the plasma
level of CRP was not inﬂuenced by the initial viral load. While the
condition of patients with H7N9 is complicated and variable, CRP,
as a conventional clinical indicator, could be a simple and
convenient marker for the early prediction of potential cytokine
storms, particularly when cytokine detection is unavailable. This
marker will contribute to the early identiﬁcation of high-risk cases,
further assessment of cytokine proﬁles of severe cases, and the
development of an appropriate therapeutic plan, such as anti-
cytokine treatment.
There are a few limitations in relation to this study. Samples
were collected at only one time-point. Continuous monitoring and
comparison of CRP and cytokine levels was also lacking. The
standard deviation of CRP was large because of the small sample
size and variable disease conditions. Further studies are necessary
to determine the exact role of hypercytokinemia in H7N9 and its
association with CRP.
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